US Pharma MarketingThe post Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority appeared first on Clinical Trials Arena.
Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority
If approved, Gilead and MSD's ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market. The post Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority appeared first on Clinical Trials Arena .
If approved, Gilead and MSD's ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market.
Source: Clinical Trials Arena